Asthma is a respiratory disorder characterized by reversible airflow limitation, bronchial hyperresponsiveness, and airway inflammation^[@R1],[@R2]^. Although it is clear that asthma is a heterogeneous syndrome, a prominent subset of asthma is characterized by type 2 inflammation with infiltration of T helper type 2 (T~H~2) cells to the airways and lung parenchyma, and a molecular signature of airway epithelial cell exposure to T~H~2 cytokines, especially interleukin 13(IL-13) ([@R3],[@R4]). IL-13 coordinates allergic lung inflammation through receptors on both structural and inflammatory cells. It induces epithelial cell hyperplasia and mucus production, airway smooth muscle cell hyperresponsiveness, and the recruitment and survival of eosinophils, which is enhanced by another T~H~2 cytokine, IL-5 ([@R5]). IL-13 is a key driver of airway inflammation in mouse models of asthma ^[@R6]^, and biomarkers of type 2 inflammation predict enhanced clinical benefit from treatment with antibodies that block IL-13 signaling such as lebrikizumab ^[@R7]^ and dupilumab ^[@R8]^.

The external signals and transcription factors that regulate T~H~2 cell differentiation are well understood. The cytokine IL-4 is both the canonical product of T~H~2 cells and a powerful driver of T~H~2 cell differentiation. Naive CD4 T cell precursors require concurrent T cell antigen receptor (TCR) and cytokine signals to induce T~H~2 differentiation. TCR ligation activates T cells through a broad signaling cascade that includes the PI(3)K and NF-κB pathways. IL-4 receptor signals activate STAT6, which upregulates GATA-3 in activated T cells. Together these two key transcription factors promote T~H~2 cell differentiation and cytokine production ^[@R9]^. Because T~H~2 cell differentiation is governed by a cytokine and transcription factor positive feedback loop, it is very sensitive to minor changes in cytokine production, the strength of TCR stimulation, and other intrinsic and environmental factors. Our extensive knowledge of the signals that control T cell differentiation and our ability to reproducibly manipulate this process *in vitro* make it an attractive system for the study of basic principles that govern gene expression networks and cell identity.

MicroRNAs (miRNAs) regulate gene expression programs by reducing the translation and stability of target mRNAs ^[@R10]^. miRNAs are grouped into families that share a network of predicted mRNA targets. Although the quantitative effect produced by each miRNA-target interaction is small, the combined effect of the network of miRNA-target interactions produces substantial changes in cell behavior. Several studies have attempted to understand miRNA functions in asthma by analyzing miRNA expression in whole lung, airway epithelial cells, or mixed peripheral blood lymphocytes from humans with asthma or mice subjected to allergic airway inflammation models ^[@R11]-[@R14]^. These studies provide insight into the effect of airway inflammation on miRNA expression patterns, but they do not define cell-intrinsic effects of miRNA regulation on disease pathogenesis.

In T cells, miRNAs regulate proliferation, survival, activation, differentiation, and cytokine production ^[@R15]^. The miR-17∼92 cluster has emerged as a particularly potent and pleiotropic regulator of T cell responses. This cluster is transcribed as a single primary miRNA transcript that is processed to produce six mature miRNAs belonging to four miRNA families: miR-17, miR-18, miR-19, and miR-92 families ^[@R16]^. Primary miR-17∼92 and the corresponding mature miRNAs are upregulated in activated CD4 T cells and can promote T cell proliferation and survival ^[@R17]-[@R20]^. Although they are expressed without apparent cell-type specificity, miRNAs in the miR-17∼92 cluster regulate the differentiation and function of several distinct T cell subsets. Both miR-17 and miR-19b promote T~H~1 and T~H~17 cell differentiation ^[@R18],[@R21]^. These two miRNAs also inhibit inducible T~reg~ cell differentiation *in vitro* ^[@R18]^, but the cluster as a whole is required for normal T~reg~ cell function *in vivo* ^[@R22]^. T~FH~ cell responses are reduced and dysregulated in the absence of miR-17∼92^[@R23],[@R24]^. However, miRNA regulation of T~H~2 cell differentiation and cytokine production remains poorly understood.

We hypothesized that miRNAs that are differentially expressed in airway-infiltrating T cells in asthma regulate T~H~2 cell function and promote lung inflammation. We used a highly sensitive nanoscale microfluidic qPCR approach to profile miRNA expression in CD4^+^ T cells isolated from human asthmatic airways^[@R25],[@R26]^. miR-19a, a member of the miR-17∼92 cluster, was significantly upregulated in asthma. Using genetically engineered mice, we found that miR-17∼92 promotes T~H~2 cytokine production *in vitro* and type 2 inflammation *in vivo*. We mapped miR-17∼92 regulation of T~H~2 cytokine production to the miR-19 family using transfectable miRNA mimics and inhibitors in primary human and mouse T cells. A functional screen of the miR-19 target network in T~H~2 cells revealed several signaling inhibitors that restrain IL-13 and IL-4 production. Taken together, our data indicate that the observed increase in T cell miR-19a expression in humans with asthma augments T~H~2 responses in their airways.

Results {#S1}
=======

miRNA expression in airway CD4 T cells {#S2}
--------------------------------------

To investigate miRNA expression in airway-infiltrating T cells, we profiled the expression of a panel of 190 miRNAs in CD4^+^ T cells sorted from bronchoalveolar lavage (BAL) fluid from 8 healthy, 13 steroid-naive asthmatic, and 21 steroid-using asthmatic subjects ([Table 1](#T1){ref-type="table"})^[@R12]^. RNA was extracted from sorted CD3^+^ CD4^+^ T cells, and miRNA expression was determined by nanoscale microfluidic qPCR on 100 pg RNA from each subject ([Supplementary Fig. 1a, Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Our analysis revealed few differences in miRNA expression between asthmatic and healthy CD4^+^ T cells from BAL with one notable exception ([Supplementary Fig. 1b, Supplementary Table 2](#SD1){ref-type="supplementary-material"}). Of the 89 miRNAs that were detected in at least 60% of the subjects, miRNA-19a was the most significantly elevated in asthma ([Fig. 1a](#F1){ref-type="fig"}, [Supplementary Table 2](#SD1){ref-type="supplementary-material"} *p* = 0.0199). miR-19a expression was consistently elevated in all of the steroid-naive asthmatic subjects with very little variability, and was similarly elevated in the steroid-using asthmatic subjects that were treated with the inhaled corticosteroid (ICS) budesonide ([Fig. 1c](#F1){ref-type="fig"}). This miRNA remained elevated in CD4^+^ T cells from steroid-naive asthmatics upon 6 weeks of ICS treatment ([Fig. 1d](#F1){ref-type="fig"}), indicating that it is resistant to gene expression changes induced by steroid treatment. Because miR-19a is a member of the miR-17∼92 cluster, a highly conserved cluster of 6 miRNAs transcribed in one polycistronic pri-miRNA, we investigated the expression of other members of the cluster. Only miR-19a, and not miR-19b, miR-17, miR-18a, or miR-20a, was differentially expressed between asthmatic and healthy CD4^+^ T cells ([Fig. 1e](#F1){ref-type="fig"}). These data demonstrate that miR-19a is specifically elevated in airway T cells in asthma, and indicate that individual members of the miR-17∼92 cluster are differentially regulated in this setting.

miR-17∼92 promotes T~H~2 cytokine production {#S3}
--------------------------------------------

The miR-17∼92 cluster regulates the differentiation and effector functions of several helper T cell subsets including T~H~1, T~H~17, T~FH~ and T~reg~ cells with varying degrees of potency ^[@R19]-[@R24]^. However, the cluster\'s role in T~H~2 cell differentiation and cytokine production, important features of the asthmatic immune response, has not been investigated. To this end, we cultured miR-17∼92-deficient CD4^+^ T cells (called '17∼92^Δ/Δ^' here), miR-17∼92-sufficient control CD4^+^ T cells (called 17∼92^+/+^ here), and transgenic miR-17∼92-overexpressing CD4^+^ T cells (called 17∼92^GFP/+^ here) in T~H~2 polarizing conditions. Intracellular cytokine staining revealed that 17∼92^GFP/+^ cells produced more of the type 2 cytokine IL-13 compared to 17∼92^+/+^ controls ([Fig. 2a](#F2){ref-type="fig"}). Conversely, fewer 17∼92^Δ/Δ^ cells produced the type 2 cytokines IL-13, IL-5, and IL-4 compared to 17∼92^+/+^ controls ([Fig. 2a-b](#F2){ref-type="fig"}). This defect in T~H~2 differentiation and cytokine production did not result in increased T~H~1 cytokine production, as measured by IFN-γ production ([Fig. 2c](#F2){ref-type="fig"}). 17∼92^Δ/Δ^ cells produced substantially more TNF, which is a known direct target of miR-19 ([Fig. 2c](#F2){ref-type="fig"}), suggesting that these cells are capable of efficient cytokine production in T~H~2-polarizing conditions, and that the defect is limited to type 2 cytokines. 17∼92^Δ/Δ^ cells produced less T~H~2 cytokines even in established GATA-3^hi^ T~H~2 cells ([Fig. 2d](#F2){ref-type="fig"}). Thus, the miR-17∼92 cluster positively regulates T~H~2 cytokine production.

To determine whether the T~H~2 cytokine defect was cell-intrinsic, we co-cultured congenically marked 17∼92^Δ/Δ^ and 17∼92^+/+^ CD4^+^ T cells in T~H~2 conditions. After 5 days in culture, the CD45.1^+^ 17∼92^Δ/Δ^ T cells produced less IL-13 and IL-4 compared to the CD45.2^+^ 17∼92^+/+^ cells ([Fig. 3a](#F3){ref-type="fig"}), demonstrating that the cytokine defect is cell-intrinsic and does not entirely depend on feedback from IL-4 or other products produced by the mutant T cells in culture.

We observed a slight proliferation defect in 17∼92^Δ/Δ^ T~H~2 cell cultures compared to 17∼92^+/+^ controls, and a slight increase in proliferation in 17∼92^GFP/+^ cells ([Fig. 3b](#F3){ref-type="fig"}). To test whether the frequency of T~H~2 cytokine-producing cells among 17∼92^Δ/Δ^, 17∼92^+/+^, and 17∼92^GFP/+^ CD4^+^ T cells was an indirect result of their rate of proliferation, we labeled the cells with Cell Trace Violet (CTV) and analyzed cytokine production at each division after 5 days of culture in T~H~2 polarizing conditions. IL-13 and IL-5 production did increase with each cell division in 17∼92^+/+^ cells. However, 17∼92^Δ/Δ^ cells produced significantly less IL-13, IL-5, and IL-4 at each cell division compared to 17∼92^+/+^ cells ([Fig. 3c, d](#F3){ref-type="fig"}). In contrast, 17∼92^GFP/+^ cells produced more IL-13 and IL-5 at each division, but an equal amount of IL-4 as compared to 17∼92^+/+^ cells ([Fig. 3c, d](#F3){ref-type="fig"}). Together these data indicate that the miR-17∼92 cluster promotes type 2 cytokine production in a cell-intrinsic and proliferation-independent manner.

miR-19 augments T~H~2 differentiation {#S4}
-------------------------------------

To understand the mechanism of miR-17∼92 control of T~H~2 cell cytokine production, the functions of individual miRNA members of the cluster need to be addressed. Therefore, we transfected mature miRNA mimics corresponding to each of the six miRNAs in the miR-17∼92 cluster into 17∼92^Δ/Δ^ CD4^+^ T cells on days 1 and 4 of T~H~2 polarizing cultures. Transfection of either miR-19a or miR-19b was sufficient to completely rescue T~H~2 cytokine production ([Fig. 4a-c](#F4){ref-type="fig"}). Other miRNAs within the cluster conferred only partial rescue of T~H~2 cytokine production compared to miR-19a or miR-19b. These data indicate that miR-19 is the primary component of the miR-17∼92 cluster that augments T~H~2 differentiation.

All of the miR-19a and the large majority of miR-19b expressed in T cells derive from the miR-17∼92 cluster ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). Consistent with this finding, specific retroviral sensors of miR-19a and miR-19b activity were strongly repressed in 17∼92^+/+^ cells, but not 17∼92^Δ/Δ^ cells ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). T cell activation induces increased transcription of the miR-17∼92 cluster, and all of the miRNAs in the cluster remain highly expressed during T~H~2 cell differentiation^[@R27]^ (and data not shown). A single transfection either early in the culture (day 1) or late (day 4) did not rescue T~H~2 cytokine production ([Fig. 4d, e](#F4){ref-type="fig"}). We conclude that miR-19 is required throughout T~H~2 cell polarization to support robust T~H~2 cell differentiation and cytokine production. miR-19 mimics also modestly increased proliferation of 17∼92^Δ/Δ^ cells in T~H~2 conditions ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}).

We next tested whether modulating the activity of miR-19 alone was sufficient to alter type 2 cytokine production in miR-17∼92-sufficient T cells with normal endogenous expression of the other miRNAs in the cluster. Transfection of miR-19a and miR-19b inhibitors into 17∼92^+/+^ T cells specifically increased the expression of corresponding GFP sensors of miR-19a and miR-19b activity and decreased expression of IL-13 ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). These inhibitors also significantly reduced IL-13, but not IL-4, production when transfected into human cord blood CD4^+^ T cells in T~H~2-polarizing cultures ([Fig. 5a, b](#F5){ref-type="fig"}). Conversely, transfection with miR-19a mimic was sufficient to increase IL-13 expression, but not IL-4, in human cord blood CD4^+^ T cells ([Fig. 5c, d](#F5){ref-type="fig"}). Similarly, 17∼92^+/+^ mouse CD4 T cells had increased IL-13 production, but not IL-4, when transfected with miR-19a or miR-19b mimics in non-polarizing conditions ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). We conclude that changes in miR-19 expression, such as those seen in human asthmatic airway T cells, are sufficient to modulate the abundance of IL-13 produced in primary human and mouse CD4^+^ T cells.

miR-19 targets *Pten*, *Socs1*, and *Tnfaip3* {#S5}
---------------------------------------------

Because a large number of direct miR-19 targets have been validated in B cell lymphomas and other cell types, we took a candidate approach to uncover how miR-19 augments T~H~2 differentiation. We individually inhibited the 38 previously validated ^[@R28]-[@R30]^ miR-19 targets that are expressed in T cells^[@R31]^ with siRNA SmartPools in 17∼92^Δ/Δ^ CD4^+^ T cells during T~H~2 polarization ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}). IL-13 and IL-4 *z*-scores were calculated for each of the transfections ([Fig. 6a, b](#F6){ref-type="fig"}). The top 8 candidate genes that when inhibited increased IL-13 and IL-4 were characterized further by inhibition with 3 individual siRNAs per gene in 17∼92^Δ/Δ^ CD4^+^ T cells during T~H~2 polarization to confirm the rescue of IL-13 and IL-4 ([Fig. 6c, d](#F6){ref-type="fig"}). The type 2 cytokine defect of 17∼92^Δ/Δ^ cells was rescued by inhibition of *Pten*, *Socs1*, and *Tnfaip3* (which encodes A20) with at least 2 out of 3 individual siRNAs ([Fig. 6e](#F6){ref-type="fig"}). Each of the top 8 candidate genes was confirmed to be inhibited by miR-19 expression by qPCR of 17∼92^Δ/Δ^ cells transfected with miR-19a, -19b, or control mimics, compared to 17∼92^+/+^ cells ([Fig. 6f](#F6){ref-type="fig"}). Furthermore, to test whether genetic depletion of PTEN expression in 17∼92^Δ/Δ^ cells could rescue T~H~2 cytokine production, we deleted one allele of *Pten* in 17∼92^Δ/Δ^ cells (17∼92^Δ/Δ^ *Pten*^Δ/+^). Genetic depletion of PTEN moderately rescued the cytokine defect of 17∼92^Δ/Δ^ T cells ([Fig. 6g](#F6){ref-type="fig"}).

*Pten, Socs1,* and *Tnfaip3* are negative regulators of T cell signaling pathways that are important for all T helper cell subsets. To test whether each of these targets regulated other T helper cell cytokines, such as IFN-γ, IL-17A, and IL-17F, we transfected 17∼92^Δ/Δ^ cells with individual siRNAs against *Pten, Socs1,* and *Tnfaip3* under non-polarizing (T~H~N), T~H~17, and T~H~2-polarizing conditions ([Fig. 6h-j](#F6){ref-type="fig"}). Consistent with previous reports ^[@R18],[@R21]^, *Pten* inhibition increased the production of all T helper cytokines tested, but reducing *Socs1* or *Tnfaip3* expression enhanced production of T~H~2 cytokines, but not IFN-γ or IL-17. Thus, miR-19 specifically regulates T~H~2 responses through distinct limiting mRNA targets.

miR-17∼92 augments T~H~2 cell function *in vivo* {#S6}
------------------------------------------------

We next tested whether reduced T~H~2 cytokine production by 17∼92^Δ/Δ^ T cells would result in altered airway type 2 inflammation *in vivo*. We transferred 17∼92^Δ/Δ^ or 17∼92^+/+^ ovalbumin (OVA)-specific OT-II T~H~2 cells to *Cd28*^-/-^ mice, and challenged the mice every 24 h oropharyngeally with OVA for 3 days ([Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}). 18 h after the last challenge, we analyzed pulmonary resistance in response to increasing doses of acetylcholine. Mice that received either no OT-II cells or 17∼92^Δ/Δ^ OT-II T~H~2 cells had significantly lower pulmonary resistance than mice that received 17∼92^+/+^ OT-II T~H~2 cells ([Fig. 7a](#F7){ref-type="fig"}), indicating that T~H~2 cells that lack the miR-17∼92 cluster are less capable of inducing allergic airway hyperresponsiveness. Histological analysis of lung sections from these mice revealed increased mucus-secreting goblet cells and more severe inflammation in mice that received 17∼92^+/+^ OT-II T~H~2 cells compared to those that received 17∼92^Δ/Δ^ OT-II T~H~2 cells ([Fig. 7b-d](#F7){ref-type="fig"}). Mice that received 17∼92^Δ/Δ^ OT-II T~H~2 cells transfected with miR-19a mimic showed a trend toward increased inflammation and mucus secretion ([Fig. 7b-d](#F7){ref-type="fig"}). To better characterize and quantify airway inflammation, we analyzed BAL from the recipient mice by flow cytometry ([Supplementary Fig. 5b](#SD1){ref-type="supplementary-material"}). Mice that received 17∼92^Δ/Δ^ OT-II T~H~2 cells had significantly reduced eosinophilia in the airways compared to mice that received 17∼92^+/+^ OT-II T~H~2 cells ([Fig. 7e](#F7){ref-type="fig"}). However, 17∼92^Δ/Δ^ OT-II T~H~2 cells transfected with miR-19a induced airway eosinophil infiltration similar to that seen in recipients of 17∼92^+/+^ OT-II T~H~2 cells ([Fig. 7e](#F7){ref-type="fig"}). Macrophage and neutrophil numbers were relatively similar in all three groups of recipients, suggesting that the differences in airway inflammation were restricted to effects induced by type 2 cytokines. We conclude that the miR-17∼92 cluster, and miR-19a specifically, has a role in the *in vivo* function of T~H~2 cells as inducers of the allergic inflammatory phenotype associated with asthma.

Discussion {#S7}
==========

Guided by miRNA expression in T cells present in the airways in human asthma, we identified a miRNA that augments T~H~2 cytokine production and allergic inflammation via coordinate regulation of cytokine and antigen receptor signaling pathways. Our data demonstrate that the miR-17∼92 cluster, and specifically miR-19a, promotes T~H~2 cytokine production by simultaneously targeting inhibitors of the NF-κB, JAK-STAT, and PI(3)K pathways. In the context of previous studies of the miR-17∼92 cluster, these findings illustrate basic principles of miRNA regulation, including the network logic of miRNA function, and how complex biological processes such as effective T cell-mediated immune responses emerge from coordinate miRNA regulation of diverse aspects of cell behavior.

The miR-17∼92 cluster has many established functions in lymphocytes^[@R32]^. The cluster as a whole promotes T cell proliferation and survival, and the differentiation and function of several committed effector T cell subsets^[@R18],[@R19],[@R21]-[@R24]^, making it an important coordinator of T cell responses. T~FH~ responses involve the concerted action of all 4 miRNA families in the miR-17∼92 cluster^[@R23],[@R24]^. miR-17 and miR-92 family miRNAs support T cell proliferation in the absence of other miRNAs^[@R20]^. In our experiments, miR-19 as well as miR-17 and miR-92 family miRNAs partially rescued 17∼92^Δ/Δ^ T cell proliferation. Both miR-17 and miR-19b promote T cell survival and T~H~1 and T~H~17 cell differentiation, while limiting iT~reg~ cell differentiation ^[@R18],[@R21]^. However, no specific functions have previously been attributed to miR-19a in T helper cells. We mapped the T~H~2 cytokine-promoting activity of the miR-17∼92 cluster to miR-19, as both miR-19a and miR-19b (but not other miRNAs in the cluster) rescued IL-13 and IL-4 production in 17∼92^Δ/Δ^ T cells.

Our study emphasizes an important concept regarding the mechanism of miRNA regulation of cell behavior: a single miRNA can be expressed in and regulate many different cell types through distinct but overlapping networks of targets. Each target may play a limiting role in distinct differentiation environments, or may play a similar role in a variety of contexts. For example, miR-19 regulated T~H~2 cytokine production in part through PTEN, a target that has widespread effects on T helper cell effector programs ^[@R18],[@R19],[@R21],[@R23]^. In contrast, SOCS1 and A20 were limiting factors for T~H~2, but not T~H~1 or T~H~17 cytokine production. The same concept applies to transcription factors and their target genes. For example, c-Maf regulates both T~H~2 and T~H~17 cytokine production through distinct molecular pathways. Similarly, GATA-3 is the principle determinant of T~H~2 cell differentiation and a direct regulator of *Il13* and *Il5,* but it also regulates T cell development in the thymus and survival in the periphery. Our findings demonstrate that careful dissection of target networks can reveal not only the mechanisms through which transcription factors and miRNAs mediate their functions, but also novel or unexpected limiting requirements for downstream genes and pathways that coordinate T cell-mediated immunity.

We identified at least three important pieces of the miR-19 target network in T~H~2 cells: *Pten, Socs1,* and *Tnfaip3*. Each of these target mRNAs encodes an inhibitor of a distinct signaling pathway, indicating that miR-19 augments T~H~2 cytokine production by simultaneously amplifying PI(3)K, JAK-STAT, and NF-κB signaling. However, our analysis revealed a limiting independent role for each target, since depleting each one individually was sufficient to markedly increase T~H~2 cytokine production. These pathways are all essential components of the antigen and cytokine signaling that induce T cell differentiation and effector function. As such, the importance of PTEN, SOCS1, and A20 for T~H~2 cytokine production have been inferred or assumed, but never tested.

PTEN inhibits the PI(3)K pathway, which promotes T cell proliferation and cell survival^[@R33]^, and deletion of one allele of *Pten* results in autoimmunity and lymphoproliferative disease in mice^[@R34]^. PTEN is an important miR-17∼92 target in T~H~1, T~H~17 and T~FH~ cell differentiation^[@R18],[@R21],[@R23],[@R24]^, but its effects on cytokine production by T~H~2 cells were previously unknown. Genetic rescue of PTEN over expression in 17∼92^Δ/Δ^ cells partially rescued T~H~2 cytokine production, indicating that both PTEN and other targets significantly contribute to the T~H~2 phenotype.

SOCS1 inhibits the JAK-STAT pathway downstream of cytokine receptors^[@R35]^, and favors T~H~17 over T~H~1 differentiation by repressing IL-12 and IFN-γ signaling^[@R36],[@R37]^. Both IFN-γ and IL-4-producing CD4^+^ T cells are increased in SOCS1-deficient mice^[@R38]^ and SOCS1 inhibits IL-4 signaling in macrophages^[@R39]^. These findings have led to speculation that SOCS1 may inhibit T~H~2 responses^[@R40]^, but this possibility had remained untested prior to our experiments. Furthermore, SOCS1 has not previously been found to be an important miR-17∼92 target in regulating the differentiation and effector functions of any helper T cell subset.

*Tnfaip3* encodes A20, a constitutively expressed negative regulator of the NF-κB pathway in T cells. A20 was identified as an important miR-19 target in macrophages^[@R30]^. Inhibition of A20 increases IL-2 production in Jurkat cells^[@R41]^, but its effect on T~H~2 cytokine production had not yet been described. While identification of these three targets leads to better understanding of the intracellular components that regulate Th2 cytokine production, genome-wide approaches to determine the full miR-19 target network in T~H~2 cells would likely reveal additional targets involved in helper T cell biology.

We hypothesized that miRNA expression profiling in airway-infiltrating T cells could reveal functionally relevant miRNAs and pathways that are directly involved in asthma pathogenesis. Indeed, we identified miR-19a as a candidate regulator of T~H~2 responses through miRNA profiling^[@R25],[@R26]^ in the small number of CD4 T cells that can be recovered from bronchoalveolar lavage. Previous studies identified miRNAs of interest by profiling expression in complex cell mixtures, such as whole lungs in animal models^[@R14]^, epithelial cell brushings^[@R12]^, or mixed lymphocytes from peripheral blood of asthmatic subjects^[@R11],[@R42]^. Interpretation of data from unseparated tissues can be ambiguous. Differential miRNA expression may reflect changes in cellular composition of samples from asthmatic subjects, and formation of mechanistic hypotheses about disease pathogenesis requires further work to identify which cell type(s) exhibit differential expression of any miRNA of interest. Future studies will be needed to confirm the observed increase in miR-19a in airway CD4^+^ T cells in asthma, and to determine whether this change is limited to T~H~2 cells in this context. Larger studies may also identify correlation between miR-19a expression and asthma severity, lung function, response to corticosteroid treatment, or biomarkers of T~H~2 inflammation that stratify asthma phenotypes^[@R1],[@R43]^.

Although clusters of miRNAs are transcribed as a single polycistronic primary miRNA (pri-miRNA) transcript, each mature miRNA in the cluster is not necessarily expressed at the same abundance in a given cell type and condition. Nevertheless, we were surprised to find a specific increase in miR-19a, but not other members of the miR-17∼92 cluster, in airway-infiltrating T cells in asthma. miR-19a and miR-19b were also preferentially increased in premalignant cells in a mouse model of B cell lymphoma and in human Burkitt\'s lymphoma cell lines^[@R16]^. A specific increase in miR-19a may be mediated by preferential processing from the polycistronic miR-17∼92 pri-miRNA transcript, or by a sequence-specific increase in the efficiency of some other step in miR-19a biogenesis. Alternatively, mature miR-19a may be specifically stabilized in T cells in inflamed lungs. Regardless of the mechanism, the observed increase in miR-19a abundance should have a significant impact on secretion of IL-13, since altering miR-19a activity by over expression or depletion in both human and mouse primary T cells altered IL-13 production *in vitro*.

The identity and function of miRNAs that regulate type 2 inflammation in a T cell-intrinsic manner have remained uncertain. miR-155 has been a major focus because miR-155-deficient T cells have a modest bias toward T~H~2 differentiation *in vitro*^[@R44],[@R45]^ and miR-155-deficient mice develop partially penetrant spontaneous airway remodeling with some of the characteristics of asthma^[@R44]^. However, these mice are resistant to experimentally induced airway inflammation^[@R46]^, suggesting that miR-155 may have a role in cell types other than T~H~2 cells in this model. Our data suggest that miR-19a upregulation in T cells in asthmatic airways may be an indicator and a cause of increased IL-13 production, and likely contributes to type 2 inflammation in asthma. Indeed, 17∼92^Δ/Δ^ T~H~2 cells induced far less airway eosinophiliathan 17∼92^+/+^ T~H~2 cells in an allergic airway inflammation model, and restoration of miR-19a was sufficient to rescue this defect.

Our study links miR-19a activity with human asthma and uncovers mechanisms of miR-19a function in T cells, suggesting that miR-19 may be an attractive drug target. Previous animal model studies have validated the concept of miRNA-based therapy by using intranasal administration of sequence-specific miRNA inhibitors to ameliorate allergic airway inflammation^[@R13],[@R47]-[@R49]^. In addition, uncovering the target networks through which miRNAs act may be an effective path to the development of novel therapies. For example, our findings lend weight to the argument that NF-κB inhibitors might be effective in asthma and other allergic diseases^[@R50]^. Through coordinate repression of several mRNA targets, miR-19 amplifies signals that augment production of T~H~2 cytokines, the principle drivers of asthma pathogenesis.

Online Methods {#S8}
==============

Human subjects {#S9}
--------------

Bronchoalveolar lavage (BAL) fluid was obtained from three groups of subjects: asthmatic subjects that had not been treated with inhaled corticosteroids (ICS) for 6 weeks prior to the study start date, called "steroid-naive" here; asthmatic subjects that were treated continuously with ICS, called "steroid-using" here, and healthy control subjects. BAL was obtained from steroid-naïve subjects at baseline and again after 8 weeks of ICS treatment, 200μg budesonide twice a day. BAL was obtained from steroid-using subjects after standardizing their ICS treatment to a regimen of 200μg budesonide twice a day for 8 weeks. This study, called the Study of the Mechanisms of Asthma (MAST), was registered on [clinicaltrials.gov](http://clinicaltrials.gov): NCT00595153. A power calculation was used to determine the number of subjects needed to measure differences in expression of 3 biomarker genes of IL-13 exposure in the airway. We utilized all sorted T cell samples available from this completed study. Inclusion and exclusion criteria for human subjects are provided on [clinicaltrials.gov](http://clinicaltrials.gov). Written informed consent was obtained from all subjects, and all studies were performed with approval from the UCSF Committee on Human Research.

Sorting of clinical BAL samples {#S10}
-------------------------------

Investigators were blinded to the group allocation of subjects during cell sorting and sample processing. Live CD3^+^ CD4^+^ T cells were sorted using a FACSAria flow cytometer (BD Biosciences, San Jose, CA) from BAL cells transported in ice cold PBS with 5% FCS within approximately four hours of collection. CD3-PE (cat\# MHCD03044) was purchased from Invitrogen (Carlsbad, CA). CD4-Cy7 (cat\# 557852), CD8-APC-Cy7 (cat\# 557834), and PI (cat\# 51-66211E) were purchased from BD Biosciences (San Jose, CA). The average purity of the sorted cells, confirmed by flow cytometric analysis, exceeded 95%. Sorted cells were washed in ice cold PBS with 2% FCS and 2 mM EDTA and then lysed in RLT buffer (Qiagen, Valencia, CA) prior to being snap-frozen and stored at -80°C.

High-throughput multiplex qPCR {#S11}
------------------------------

High-throughput multiplex qPCR was performed according to a previously described protocol^[@R26]^. Briefly, CD4 T cells sorted by flow cytometry from clinical samples were lysed and stored in RLT buffer (Qiagen) at -80°C until all samples were collected. Frozen lysates were thawed and loaded onto QIAshredder homogenizer columns (Qiagen). Using a low concentration of ethanol (35% v/v), the large fraction of RNA (\>150nt) was precipitated and captured on collection columns (RNeasy, Qiagen). The small fraction of RNA (\<150nt) does not bind with low concentration of RNA, and so the flow-through from the first column was brought up to a concentration of 75% v/v ethanol and RNA was precipitated and collected on a fresh column (MinElute, Qiagen). Both RNA fractions were treated with DNase per manufacturer\'s recommendations (Qiagen). 2μl of RNA from each large fraction, as well as a standard curve of RNA from *in vitro*-derived T~H~2 cells, were reverse transcribed using the SuperScript III kit (Invitrogen). RNA was then quantified by qPCR using primers for *β2m* and comparing to the standard curve of RNA. We calculated 100pg RNA from the small fraction for each sample for multiplex reverse transcription using 2 separate mixes of 96 miRNA stem loop reverse primers at a final concentration of 1 nM ([Supplemental table 1](#SD1){ref-type="supplementary-material"}). Reverse transcription and 20 cycles of preamplification were performed according to previous protocols^[@R25],[@R26]^. Excess primers were removed from samples using 9μl ExoSAP-IT (USB) per sample, and then 15μl of each sample was purified on Illustra AutoScreen-96 Well Plates (GE Healthcare). MiRNA qPCR data was collected on the BioMark system (Fluidigm) using a 96.96 Dynamic Array Integrated Fluidic Circuit (IFC).

Fluidigm Biomark qPCR data analysis {#S12}
-----------------------------------

Data was first analyzed on Real Time PCR Analysis software (Fluidigm) with the quality threshold set at 0.5, baseline correction set to linear (derivative), and Ct threshold method set to auto (detectors). The data was further analyzed in R (version 2.14.1) through the following pipeline: Ct values \< 5 or \>28 were removed per Fluidigm recommendations: miRNAs that were detected in less than 60% of patient samples were removed from analysis; missing Ct values were replaced with the limit of detection (highest Ct value within the standard curve) + 0.1, and 4) the data were global mean-normalized per plate to account for inter-plate differences.

Mice {#S13}
----

Mice with *lox*P-flanked alleles encoding miR-17∼92 (*Mirc1*^fl/fl^, 008458, The Jackson Laboratory), and *Rosa26*-miR-17∼92--transgenic mice (Gt(ROSA)26Sor^tm3(CAG-MIR17-92,-EGFP)Rsky^, 008517, The Jackson Laboratory) were crossed to CD4-Cre mice (4196, Taconic) to generate CD4-Cre; *Mirc1*^fl/fl^ (called '17∼92^Δ/Δ^' here), CD4-Cre;Gt(ROSA)26Sor^tm3(CAG-MIR17-92,-EGFP)Rsky^ (called '17∼92^GFP/+^' here), and CD4-Cre; *Mirc1*^+/+^ or *Mirc1*^fl/fl^; (collectively called '17∼92^+/+^' here). OT-II mice (004194), and mice heterozygous for the *Rora*^sg^ mutation (002651) were from The Jackson Laboratory. Mice with *lox*P-flanked *Pten* alleles have been described^[@R51]^. *Cd28*^-/-^ mice (002666) were from The Jackson Laboratory. All mice were housed and bred in the specific pathogen-free barrier facility at the University of California, San Francisco. The Institutional Animal Care and Use Committee at the University of California, San Francisco, approved all animal experiments.

*In vitro* human cord blood T cell polarization {#S14}
-----------------------------------------------

Peripheral blood mononuclear cells (PBMCs) from anonymous human cord blood donors were isolated by Lymphoprep gradient (Accurate Chemical & Scientific Corp; cat \# 1114545). CD4^+^ T cells were isolated from PBMCs using the Dynabeads Untouched Human CD4^+^ T Cell Isolation Kit (Invitrogen). Cells were stimulated for ∼65 h on plates coated with 1μg/ml anti-CD3 (UCSF Monoclonal Antibody Core; clone OKT-3) and 2μg/ml anti-CD28 (UCSF Monoclonal Antibody Core; clone 9.3) at an initial density of 0.7×10^6^ cells/ml. After stimulation, the cells were rested for two days in media containing 20 units/ml recombinant human IL-2 (NCI). For T~H~2 polarizing conditions, 12.5 ng/ml recombinant human IL-4 (PeproTech; cat \# 200-04) was added throughout the 5 days. T cell culture was in RPMI-1640 media with 10% FCS, pyruvate, nonessential amino acids, L-arginine, L-asparagine, L-glutamine, folic acid, beta mercaptoethanol, penicillin, and streptomycin.

*In vitro* mouse primary T cell polarization {#S15}
--------------------------------------------

CD4^+^ T cells were isolated from spleen and lymph nodes of young mice (4-8 weeks old) using the Mouse CD4 Dynabeads Isolation kit (Invitrogen; L3T4). For experiments including Cell Trace Violet (Invitrogen), cells were stained at 5μM in PBS for 20 minutes at 37°C, quenched with 5 volumes of media with 10% FCS for 5 minutes, and washed twice in media prior to culture. For all conditions, cells were activated with hamster anti-mouse anti-CD3 (clone 2C11, 0.25μg/ml) and anti-mouse CD28 (clone 37.51, 1μg/ml) antibodies on a plate coated with goat anti-hamster IgG (0.3 mg/ml in PBS; MP Biomedicals) for ∼65 h at an initial density of 0.7×10^6^ cells/ml, and then rested in media with 20 units/ml recombinant IL-2 (National Cancer Institute) for 48-72 h. For T~H~2 polarizing conditions, 500 units/ml IL-4 supernatant and 5μg/ml anti-IFN-γ(clone XMG1.2) were added to the culture throughout the 5-6 days. "Low T~H~2" conditions included only 5 units/ml IL-4, and "T~H~N" conditions received no polarizing cytokines or antibodies. T~H~17 polarizing conditions received 5ng/ml recombinant human TGF-β (Peprotech), 25ng/ml recombinant murine IL-6 (Peprotech), 10ug/ml anti-IL-4 (clone 11B11), 10ug/ml anti-IFN-g, and 20ng/ml recombinant murine IL-23 (R&D Systems) throughout the 5 days of culture. All cultures used DMEM high glucose media supplemented with 10% FCS, pyruvate, nonessential amino acids, MEM vitamins, L-arginine, L-asparagine, L-glutamine, folic acid, beta mercaptoethanol, penicillin, and streptomycin.

miRNA mimics, miRNA inhibitors, siRNA, and miRNA sensors {#S16}
--------------------------------------------------------

During *in vitro* polarization, human or mouse primary CD4^+^ T cells in culture were transfected with miRNA mimics, inhibitors, or siRNAs (Dharmacon) at 24 and 96 h of culture. miRIDIAN miRNA mimics were used at 500nM per transfection. miRIDIAN miRNA Hairpin Inhibitors were also used at 500 nM. siGENOME SmartPools and ON-TARGET plus Individual siRNA were used at 500 nM. Cells were transfected using the Neon Transfection system by Invitrogen as described^[@R20]^. Retroviral miRNA sensors containing 4 perfectly complementary binding sites for miR-1, miR-19a, and miR-19b were constructed and transduced at 48 h as described^[@R20]^.

Intracellular cytokine and transcription factors stains {#S17}
-------------------------------------------------------

For cytokine staining, cells were restimulated with 20 nM PMA and 1μM ionomycin for 4 hours, and 5μg/ml brefeldin A was added during the last 2 hours of restimulation. Cells were stained with the viability dye eFluor780 (eBiosciences; Cat \# 65-0865-14), and then fixed in 4% paraformaldehyde for 8 minutes at room temperature. Cytokine staining was done in permeabilization buffer containing 0.05% saponin. For transcription factor staining, unstimulated cells were fixed, permeabilized, and stained using the FoxP3 Staining Kit (eBiosciences; Cat \# 00-5523-00). Samples were analyzed with a flow cytometer (BD LSR II). Mouse antibodies: IL-13-PE (eBiosciences; eBio13A), IL-4-APC (eBiosciences; 11B11), IL-5-PE (Biolegend; TRFK5), IFNg-FITC (eBiosciences; XMG1.2), TNFa-AlexaFluor700 (BD Biosciences; MP6-XT22), and GATA-3-PE (eBiosciences; E50-2440). Human antibodies: IL-13-FITC (eBiosciences; PVM13-1), IL-4-APC (BD Biosciences; 8D4-8), IL-17A-eFluor450 (eBiosciences; eBio17B7), and IL-17F-PE (BD Pharmingen; 079-289).

*In vivo* allergic airway inflammation model {#S18}
--------------------------------------------

For each *in vivo* experiment, we used at least 5 mice per group to gain power for statistical analysis, and repeated the model to pool data and determine reproducibility. Mice received 3 different cell types in rotation such that each cage had 1-2 recipients for each cell type. Mice were challenged in random order and were tested for pulmonary resistance in rotating order through each group. One mouse was removed from analysis due to low body weight and lack of movement; histological analysis confirmed signs of emphysema. Six- to eight-week old sex-matched littermate *Cd28*^-/-^ mice were injected retro-orbitally with 2×10^5^ *in vitro* T~H~2-polarized 17∼92^+/+^ or 17∼92^Δ/Δ^ OT-II cells. The mice were challenged oropharyngeally with 50μg ovalbumin (OVA) in PBS at 24, 48, and 72 hours post transfer to induce allergic airway inflammation. 18 hours after the final challenge, mice were anesthetized with ketamine/xyalazine, and pulmonary resistance was measured by trachaea cannulation in response to intravenous acetylcholine, as previously described ^[@R52]^. BAL was collected by 5 lavages of 0.8 ml of PBS for flow cytometry, and lungs were filled with 10% buffered formalin and fixed for histology. BAL cells were washed, counted, and surface stained for analysis by flow cytometry. Antibodies used for myeloid cell enumeration: CD11b-AlexaFluor488 (eBiosciences; M1/70), CD11c-PE-Cy7 (Biolegend; N418), Ly6G-V450 (BD Biosciences; 1A8), SiglecF-PE (BD Biosciences; E50-2440). Two paraffin-embedded 5 μm sections of the whole lung from each mouse were stained with H&E and PAS. To quantify inflammation, H&E-stained lung sections were de-identified for blinding and scored for peribronchial and perivascular inflammatory cell infiltration: grade 0, no infiltration; grade 1, \<25% of examined area; grade 2, 25-50%; grade 3, 51-75%; and grade 4, \>75%. To quantify goblet cell hyperplasia, PAS stained lung sections were de-identified for blinding and scored for the percentage of PAS positive cells among airway epithelial cells: grade 0: none; grade 1 \<25% of airway epithelial cells; grade 2, 25-50%; grade 3, 51-75%; and grade 4, \>75%.
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![miR-19a expression is elevated in CD4^+^ T cells from asthmatic lungs\
(**a**) Taqmanq PCR analysis of miRNA expression in sorted CD4 T cells. Circles represent global-mean-normalized average miRNA expression in asthma compared to healthy subjects. Dashed lines represent 2-fold higher or lower expression. (**b**) qPCR analysis of miR-19a expression normalized to the global mean. Circles represent individual subjects. Line represents mean expression for each group. (**c**) qPCR analysis of miR-19a expression in CD4^+^ T cells from individual asthmatic subjects pre- and post- 6 weeks of inhaled corticosteroid (ICS) treatment*. n* = 5. (**d**) qPCR analysis of the expression of miR-17, miR-18a, miR-19b, and miR-20a (members of the miR-17∼92 cluster; miR-92a was not detected in this experiment) normalized to the global mean. Circles represent individual subjects. Lines represent mean expression for each group.(**a-d**) Data are pooled from 2 experiments with *n* = 8 Healthy, 13 steroid-naïve (SN) asthma, and 21 steroid-using (SU) asthma. (**b, d**) One-way ANOVA with Dunnett\'s post test (compared to healthy). (**c**) Paired 2-tailed t-test. \*p \< 0.05, \*\**p* \< 0.0001, ns = not significant.](nihms633107f1){#F1}

![The miR-17∼92 cluster promotes T~H~2 cytokine production\
(**a-c**) Intracellular cytokine staining and pooled analysis of day 5 T~H~2-polarized CD4^+^ T cells from 17∼92^Δ/Δ^ (left), 17∼92^+/+^ (middle), and 17∼92^GFP/+^ (right) mice. Numbers in quadrants indicate percentage of cells producing the indicated cytokine among live singlets. Bar graphs indicate total cytokine^+^ cells as a percentage of live singlets. Error bars are mean ± SEM. (**a**) Flow cytometry data is representative of 11 independent experiments. *n*= 12 17∼92^Δ/Δ^ (black), 17 17∼92^+/+^ (grey), and 6 17∼92^GFP/+^ (white) mice pooled from 11 independent experiments. (**b**) Flow cytometry data is representative of 7 independent experiments. *n* = 8 17∼92^Δ/Δ^ (black), 10 17∼92^+/+^ (grey), and 4 17∼92^GFP/+^ (white) mice pooled from 7 independent experiments. (**c**) Flow cytometry data is representative of 11 independent experiments. *n* = 12 17∼92^Δ/Δ^ (black), 17 17∼92^+/+^ (grey), and 7 17∼92^GFP/+^ (white) mice pooled from11 independent experiments. (**d**) Flow cytometry of GATA-3 expression in day 5 T~H~2-polarized CD4 T cells from 17∼92^Δ/Δ^ (black line), 17∼92^+/+^ (grey filled), and 17∼92^GFP/+^ (black dashed line) mice. Data are representative of 2 experiments. Bar graph indicates mean fluorescence intensity (MFI) of GATA-3 expression in live singlets of 17∼92^Δ/Δ^ (black), 17∼92^+/+^ (grey), and 17∼92^GFP/+^ (white) mice. Error bars are mean ± SEM. *n* = 4, 4, 4 (2 mice in each group with duplicate cultures from 2 independent experiments). (**a, c, d**) One-way ANOVA with Dunnett\'spost test. (**b**) One-way ANOVA Kruskal-Wallis test (for groups with unequal variance) and Dunn\'s post test. \**p*\< 0.05, \*\**p*\< 0.001, ns = not significant.](nihms633107f2){#F2}

![The miR-17∼92 cluster promotes T~H~2 cytokine production in a cell-intrinsic and proliferation-independent manner\
(**a**) Intracellular cytokine staining of CD4^+^ T cells from CD45.1^+^ 17∼92^Δ/Δ^ and CD45.2^+^ 17∼92^+/+^ mice, co-cultured in T~H~2 polarizing conditions for 5 days. Numbers indicate percentage of cytokine-producing cells (above the dotted line) in either the CD45.1^+^ or the CD45.1^−^ gate (solid boxes). Data are representative of 2 independent experiments with 2 mice each and duplicate cultures. (**b**) Cell Trace Violet (CTV) stain indicating proliferation of day 5 T~H~2-polarized 17∼92^Δ/Δ^ (black line), 17∼92^+/+^ (grey filled), and 17∼92^GFP/+^ (black dashed line) CD4^+^ T cells. Numbers above peaks indicate division number relative to an undivided control. (**c**) Intracellular cytokine staining of CTV-labeled 17∼92^Δ/Δ^ (left), 17∼92^+/+^ (middle), and 17∼92^GFP/+^ (right) day 5 T~H~2-polarized CD4^+^ T cells. Solid box indicates cytokine-positive gate used for quantification in (**d**). (**d**) Quantification of (**c**) showing cytokine-positive cells (as a percentage of live singlets) at each division in 17∼92^Δ/Δ^ (black bars), 17∼92^+/+^ (grey bars), and 17∼92^GFP/+^ (white bars) cells. Data are from one representative experiment. Error bars are mean with range. *n* = 2 replicate cultures from one mouse of each genotype. *p* \< 0.0001 by 2-way ANOVA comparing 17∼92^Δ/Δ^ and 17∼92^+/+^ in IL-13, IL-5, and IL-4. *p* \< 0.0001 by 2-way ANOVA comparing 17∼92^+/+^ and 17∼92^GFP/+^ in IL-13 and IL-5. *p* = 0.3153 by 2-way ANOVA comparing 17∼92^+/+^ and 17∼92^GFP/+^ in IL-4. (**b-d**) Data are representative of 6 independent experiments with 17∼92^Δ/Δ^ and 17∼92^+/+^ (*n* = 6 mice each), and 2 experiments with 17∼92^+/+^ and 17∼92^GFP/+^ (*n* = 2 mice each).](nihms633107f3){#F3}

![miR-19a and miR-19b rescue the T~H~2 cytokine defect in 17∼92^Δ/Δ^ cells\
(**a**) Intracellular cytokine staining of 17∼92^+/+^ or 17∼92^Δ/Δ^ CD4 T cells transfected with control mimic (CM), miR-19a, -19b, -17, -18a, -20a, or -92a mimics. Cells were transfected on days 1 and 4 of T~H~2 polarization, and analyzed on day 5. Numbers in each quadrant indicate percentage of cells producing the indicated cytokine. Data are representative of 3 independent experiments. (**b-c**) Quantification of IL-13 (**b**) or IL-4 (**c**) production at day 5 after transfection with miRNA mimics. Bars represent mean ± SEM for 3 individual transfections for each condition. Data are representative of 3 independent experiments. (**d-e**) 17∼92^+/+^ or 17∼92^Δ/Δ^ CD4^+^ T cells were transfected with CM, miR-19a, or -19b on day 1 only, day 4 only, or both day 1 and 4. Quantification of IL-13 (**d**) or IL-4 (**e**) production at day 5 of T~H~2 polarization. Error bars are mean ± SEM for 3 individual transfections for each condition. Data are representative of 2 independent experiments. (**b, c**) One-way ANOVA with Dunnett\'s post test (comparing each column to 17∼92^Δ/Δ^ + CM). (**d, e**) *p*\< 0.0001 by 2-way ANOVA with Bonferroni post test (comparing each column to 17∼92^Δ/Δ^ + CM per time point). ns = "not significant", \**p*\< 0.05, \*\* *p* \< 0.01, \*\*\* *p* \< 0.001, \*\*\*\**p* \< 0.0001.](nihms633107f4){#F4}

![miR-19a promotes IL-13 production in human CD4^+^ T cells\
(**a**) Intracellular cytokine staining of CD4^+^ T cells isolated from human cord blood and transfected with control inhibitor or anti-miR-19 inhibitor on days 1 and 4 in T~H~2 polarizing conditions, analyzed on day 5. Numbers in each quadrant indicate percentage of cytokine-positive cells. Data are representative of 3 experiments with 8 cord blood samples. (**b**) Quantification of IL-13 (left) or IL-4 (right) producing human CD4^+^ T cells upon transfection with control inhibitor (CI) or anti-miR-19 inhibitor (Anti-19). Circles represent the mean of 2 individual transfections of each inhibitor. Lines connect individual cord blood donors receiving either inhibitor. *n* = 8 cord bloods in 3 experiments. (**c**) Intracellular cytokine staining of CD4^+^ T cells isolated from human cord blood and transfected with control mimic or miR-19a mimic on days 1 and 4 in T~H~2 polarizing conditions, analyzed on day 5. Numbers in each quadrant indicate percentage of cytokine-positive cells. Data are representative of 3 experiments with 8 cord blood samples. (**d**) Quantification of IL-13 (left) or IL-4 (right) producing human CD4^+^ T cells upon transfection with control mimic (CM) or miR-19a mimic (19a). Circles represent the mean of 2 individual transfections of each mimic. Lines connect individual cord blood donors receiving either mimic. *n* = 8 cord bloods in 3 experiments. (**b, d**) Two-tailed paired t-test. \**p* \< 0.01, \*\**p* \< 0.001, ns = not significant.](nihms633107f5){#F5}

![Several miR-19 targets negatively regulate T~H~2 cytokine production\
(**a-b**) Primary screen of miR-19 targets that alter IL-13 and IL-4 production. Analysis of intracellular cytokine staining of 17∼92^Δ/Δ^ cells transfected with 38 siRNA smart pools. Bars indicate IL-13 *z*-score (*z* = x -- mean/SD where x represents the IL-13^+^ cells (%) for each siRNA (**a**) or IL-4 *z*-score (**b**). The white bar indicates siRNA nontargeting control (siNegCtl), and the black bar indicates miR-19a mimic positive control. The shaded grey area highlights the 8 genes with further analysis in (**c**) and (**d**). Data are representative of two independent experiments. (**c-d**) Analysis of intracellular cytokine staining of 17∼92^Δ/Δ^ cells transfected with 3 individual siRNAs against the top 8 candidate genes identified in (**a**) and (**b**). Bars indicate IL-13^+^ (**c**) and IL-4^+^ (**d**) cells as a percentage of live singlets. The white bar indicates siNegCtl, and the black bar indicates miR-19a mimic. Dashed lines indicate the range between the negative and positive controls. Data are representative of 2 independent experiments. (**e**) Intracellular cytokine staining of 17∼92^Δ/Δ^ cells transfected with individual siRNAs against *Socs1, Tnfaip3,* and *Pten* compared to siNegCtl. Numbers in each quadrant indicate percent of cytokine-positive cells. Data are representative of 4 independent experiments. (**f**) qPCR expression of the top 8 candidate miR-19a targets in 17∼92^Δ/Δ^ cells transfected with control (CM, black bars), miR-19a (dark grey bars), miR-19b (light grey bars) mimics, or 17∼92^+/+^ cells transfected with CM (white bars). Data are normalized to *Gapdh*. Data are representative of 2 independent experiments. Error bars represent mean with range of 2 technical replicates. (**g**) Intracellular cytokine stain of day 5 "Low T~H~2"-polarized cells from 17∼92^Δ/Δ^ *Pten*^+/+^ (left), 17∼92^Δ/Δ^ *Pten*^+/-^ (middle), and 17∼92^+/+^ *Pten*^+/+^ mice. Numbers in each quadrant indicate percent of cytokine-positive cells. Data are representative of two experiments. (**h-j**) Analysis of intracellular cytokine staining of 17∼92^Δ/Δ^ cells in non-polarizing (**h**), T~H~17 polarizing (**i**), or T~H~2 polarizing (**j**) conditions transfected with individual siRNAs against *Socs1, Tnfaip3,* and *Pten*, compared to siNegCtl. Bars represent mean with range. *n* = 2 transfections for each condition. Data are representative of 2 independent experiments.](nihms633107f6){#F6}

![The miR-17∼92 cluster promotes T~H~2-driven inflammation *in vivo*\
(**a**) Pulmonary resistance measures at day 4 in response to increasing doses of acetylcholine. Circles represent mean of 10 mice receiving 17∼92^+/+^ OT-II cells (black line open circles), 10 mice receiving 17∼92^Δ/Δ^ OT-II cells (black line black circles), and 6 mice receiving no cells (grey dashed line open circles). Error bars represent mean ± SEM. Statistics on the plot indicate differences at the highest dose of acetylcholine. Data from 2 experiments were combined. (**b**) Representative Periodic Acid Schiff (PAS) staining of lung sections from recipient mice with 17∼92^+/+^ OT-II cells transfected with control mimic (CM) (left; *n* = 10), 17∼92^Δ/Δ^ OT-II cells transfected with CM (middle; *n* = 10), or 17∼92^Δ/Δ^ OT-II transfected with miR-19a mimic (right; *n* = 9). Images are representative of 2 experiments. Black arrowheads mark PAS^+^ cells. The area between the dotted lines indicates immune cell infiltration. (**c-d**) Histologic scores of PAS staining (**c**) to quantify mucus-secreting cells, and H&E staining (**d**) to quantify airway inflammation. Error bars represent median with inter quartile range. Analyses use a scale 0-4 and are analyzed by a blinded observer.(**e**) Analysis of flow cytometry of inflammatory cells in the BAL on day 4. Eosinophils (CD11b^+^ Siglec F^+^, left), neutrophils (CD11b^+^ Ly6G^+^, middle), and alveolar macrophages (CD11c^+^ Siglec F^+^, right) were quantified as the product of their frequency among live cells and the total BAL cell count. Error bars represent mean ± SEM. *n* = 15, 19, and 19. (**a**) Two-way ANOVA with Bonferroni post-tests. (**c-e**) One-way ANOVA with Dunnett\'s post test. \**p* \< 0.05, \*\**p* \< 0.001, \*\*\**p* \< 0.0001. ns = not significant.](nihms633107f7){#F7}

###### Healthy and asthmatic subjects providing bronchoalveolar lavage CD4 T cells for miRNA expression analysis

                                       Healthy        Steroid-naïve Asthma   Steroid-using Asthma
  ------------------------------------ -------------- ---------------------- ----------------------
  Sample size (M/F)                    8 (4/4)        14 (5/9)               21 (9/12)
  Age, y                               40.3 (25-56)   30.1 (20-56)           37.3 (18-55)
  FEV1 % predicted                     100 (88-128)   90 (61-103)            80 (59-110)
  **Methacholine PC~20~ mg/ml**        \>10           0.8 (0.08-4.3)         2.1 (0.14-8.1)
  **Sorted CD4^+^ T cells (×10^3^)**   215 (24-440)   243 (29-1,250)         277 (45-2,200)
